Mechanisms of Tyrosine Kinase Inhibitor Resistance in GI Stromal Tumors

胃肠道间质瘤酪氨酸激酶抑制剂耐药机制

• 批准号: 7789445
• 负责人: Michael C Heinrich
• 金额: --
• 依托单位: PORTLAND VA MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-04-01 至 2013-04-01
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7789445
• 关键词: Accounting; Acute Myelocytic Leukemia; Adult; Adverse effects; Adverse reactions; Age; Alleles; American; Apoptosis; BAY 54-9085; Biochemical; Biological Assay; Biological Models; Budgets; Cancer Biology; Caring; Cell Line; Cell model; Cells; Chinese Hamster Ovary Cell; Clinical; Clinical Trials; Cloning; Colon Carcinoma; Combined Modality Therapy; Comorbidity; Cytoplasmic Tail; Cytotoxic agent; DNA; Dasatinib; Development; Diabetes Mellitus; Diagnosis; Drug resistance; Effectiveness; Ethylnitrosourea; Frequencies; Gastrointestinal Stromal Tumors; Genomics; Genotype; Health; Healthcare; High Pressure Liquid Chromatography; Hospitalization; Imatinib; In Vitro; Investigation; Laboratories; Life; Maintenance; Malignant Neoplasms; Malignant neoplasm of lung; Malignant neoplasm of prostate; Mass Spectrum Analysis; Measurement; Modeling; Morbidity - disease rate; Mucositis; Mutagenesis; Mutation; Neutropenic Fever; Oncogenic; PDGFRA gene; Pathway interactions; Patients; Pattern; Pharmaceutical Preparations; Phosphorylation; Phosphotransferases; Play; Principal Investigator; Pulmonary Heart Disease; Quality of life; Radiation; Receptor Protein-Tyrosine Kinases; Recurrence; Research; Resistance; Risk; Role; Seminoma; Signal Transduction; Signaling Molecule; Solid Neoplasm; Specimen; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Stromal Neoplasm; System; Techniques; Testing; Therapeutic Agents; Time; Toxic effect; Transfection; Treatment outcome; Tumor Biology; Tyrosine Kinase Inhibitor; Unresectable; Variant; Veterans; advanced disease; base; cancer care; cancer therapy; chemotherapy; clinically relevant; conventional therapy; cost; extracellular; improved; inhibitor/antagonist; insight; kinase inhibitor; malignant breast neoplasm; mastocytosis; medical complication; melanoma; mortality; mutant; novel; novel therapeutics; prevent; programs; research study; resistance mechanism; sarcoma; small molecule; soft tissue; treatment strategy; tumor; tumor progression